Treeline Biosciences emerged from stealth with a $200 million Series A extension, raising its total funding to over $1.1 billion. The Massachusetts-based biotech disclosed its lead cancer drug candidates, including TLN-121, a protein degrader targeting BCL6 in lymphoma; a broad KRAS mutant inhibitor for solid tumors; and a licensed EZH2 inhibitor from Jiangsu Hengrui Pharmaceuticals for T cell lymphomas. Treeline’s multi-program approach deviates from conventional milestone-based funding, enabling parallel development of complementary oncology therapies. Its robust financing and pipeline position it as a significant emerging player in cancer therapeutics.